Month: March 2026

Company announcement – inside information No. 20/2026                                                  26 March 2026 Netcompany raises full-year margin guidance for 2026 Netcompany’s continued focus on delivery excellence and implementation, supported by the ongoing embedding of AI capabilities into our methodology has led to increased expectation for adjusted EBITDA margin for the full-year 2026. “As a leading European provider of complex IT solutions in regulated environments across public and private sectors, we constantly strive to become better at what we do. The continuous investment over recent years in AI-embedded platforms and products and responsible AI executable methodology has positioned Netcompany as a European leader in delivering and/or renovating highly complex high-quality systems on time and within budget with reduced...

CHICAGO, March 26, 2026 (GLOBE NEWSWIRE) — XA Investments LLC (XAI), a Chicago-based alternative investment management and consulting firm, announced that Lauren Michalak has joined the firm as a managing director and head of product development and strategy, leading efforts in those areas for the firm’s proprietary closed-end funds. She will also serve the firm’s interval fund consulting clients and research clients. “Lauren has spent two decades operating at the intersection of product innovation, strategy, and enterprise execution. She has led every stage of the product development lifecycle across multiple fund structures, raised over $15 billion of new capital, and driven complex, cross-functional initiatives—bringing the discipline needed to turn ideas into market-ready offerings. We’re excited for her to help shape the next...

Sanoma Corporation, Stock exchange release, 26 March 2026 at 18:30 EET SANOMA CORPORATION: ACQUISITION OF OWN SHARES 26 March 2026 Nasdaq Helsinki Ltd:Date 26 March 2026  Exchange transaction Buy  Share class SANOMA  Amount 22,000  Average price/share, EUR 9.0884  Highest price/share, EUR 9.1100  Lowest price/share, EUR 9.0200  Total cost, EUR 199,944.80       The share buybacks are executed in compliance with Regulation No. 596/2014 of the European Parliament and Council (MAR) Article 5 and the Commission Delegated Regulation (EU) 2016/1052. The company holds a total of 1,075,392 of its own shares (SANOMA) including the shares acquired on 26 March 2026. Detailed information concerning the acquisition is attached to this stock exchange release. On behalf of Sanoma Corporation Skandinaviska Enskilda Banken...

March 26, 2026 MONTHLY DISCLOSURE OF THE TOTAL NUMBER OF SHARES AND VOTING RIGHTS Articles L. 233-8 II of the Commercial Code and 223-16 of the General Regulation of the AMFDate   Shares   Voting rightsTheoretical* Exercisable**28 February 2026 43,203,225 49,276,265 49,093,732*This number is calculated on the basis of all the shares to which voting rights are attached, including shares which voting rights have been suspended, in accordance with Article 223-11 of the AMF general regulation related to the calculation of the crossing of thresholds with regard to the number of voting rights. **For information purposes, this number excludes the shares which voting rights have been suspended. The information is also available in the « Regulated Information » section of the Ipsos website: https://www.ipsos.com/en/regulated-informations/en....

Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue GrowthTevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue GrowthPotential transaction expected to add $20M+ in revenue and support double-digit growth, further strengthening Tevogen’s position in oncology, rare diseases, and medical devices Target CRO operates across 20+ countries, providing global clinical development capabilitiesWARREN, N.J., March 26, 2026 (GLOBE NEWSWIRE) — Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that it is in advanced-stage evaluation of a niche contract research organization (CRO) with multi-country operations and established relationships across oncology, rare diseases, and medical devices. If...

Strasbourg, France, March 26, 2026, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced a 30-minute oral presentation on TG4050, the Company’s Individualized Neoantigen Therapeutic Vaccine (INTV) at the World Vaccine Congress (WVC), taking place from March 31 to April 2, 2026, in Washington, D.C., USA. The presentation will be held on April 1st. The presentation will highlight findings of the Phase 1 part of the ongoing Phase 1/2 trial in head and neck cancer. Transgene will also discuss the potential of INTVs to reshape early-stage cancer treatment. “We are delighted to share our positive data on our lead asset TG4050 with the scientific community”, said Katell Bidet Huang, PhD, Head of Translational Medicine at Transgene.“TG4050...

Flow Traders 1Q 2026 Pre-Close Call Amsterdam, the Netherlands – Flow Traders Ltd. (Euronext: FLOW) publishes the 1Q 2026 pre-close call script to be used with analysts post the market close on 26 March 2026. Welcome to the Flow Traders 1Q 2026 pre-close call, which is being conducted post the European market close on 26 March. During this call we will highlight relevant publicly available data and industry trends in our markets and relate these data points to their impact on our business for the quarter. The silent period for the first quarter has started on 24 March and we will publish our 1Q 2026 results on 24 April at 07:30 CET. Market Environment Market trading volumes and volatility in the first quarter across most asset classes and regions were relatively higher both year-on-year and quarter-on-quarter. Geopolitical tensions...

Lyon (France), March 26, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced its participation in the upcoming 26th World Vaccine Congress, which will take place from March 31 to April 2, 2026 at the Walter E. convention center in Washington, D.C. Led by the Company´s Chief Executive Officer, Thomas Lingelbach, a team of Valneva´s senior executives will participate in multiple events throughout the conference. On April 1, 2026, at 9:40 am EST, Susanne Eder-Lingelbach, Vice President Clinical Development at Valneva, will present “Vaccine Development updates for chikungunya – Phase IV and real-world evidence studies”. Valneva and its partner Instituto Butantan recently announced the launch of a pilot vaccination campaign with Valneva’s single shot chikungunya vaccine IXCHIQ® in Brazil,...

DEME today released its Annual Report 2025, which provides a comprehensive overview of the group’s strategy, operational performance, ESG progress, and financial results. It is the fourth such report since the company’s stock listing in 2022. As announced at the end of February 2026, last year proved to be yet another record year for DEME, with all-time high profitability, building on the strong momentum of previous years. 2026 is also shaping up to be a milestone year as DEME is celebrating its 150th anniversary.AttachmentP2026 DEME Publication Annual Report 20260326 ENG

LIBERTY, Mo., March 26, 2026 (GLOBE NEWSWIRE) — Innovation, safety, and technology are shaping the world around us, especially in the propane industry. That is why Ferrellgas Partners, L.P. (OTC: FGPR) is proud to announce that Director of Logistics Raudel Arriaga has been selected as one of Samsara’s 100 Fleet Operators to Watch in 2026. The program highlights transportation and logistics leaders who are redefining what safety means and how it impacts our lives and our future. “At Ferrellgas, safety, fleet stewardship, and operational discipline all go hand in hand,” said Arriaga. “Our employee-owners take pride in the trucks they operate and the customers they serve. The connected fleet technology we’ve implemented helps us support them with better visibility and coordination across our network. I’m honored by the recognition,...